Short answer
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Third-quarter fiscal 2026 results announced for the period ended September 30, 2026.
RHYTHM PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter fiscal 2026 results announced for the period ended September 30, 2026
- Full financial results available in furnished Exhibit 99.1, the company’s accompanying press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 product revenue $92.1M, up 29% sequentially and 80% year over year, signaling accelerating IMCIVREE commercialization
- Acquired HO launch generated 700+ U.S. patient start forms from 500+ prescribers by September 30
- U.S. revenue $67.5M, up 32% sequentially, while ex-U.S. revenue reached $24.7M, up 22%
- Bivamelagon royalty amendment requires $350M over four years, reducing future MC4R portfolio royalties to 1%
- New five-year term loan provides up to $750M, including a $250M initial draw, strengthening funding for pivotal development and launches
Item EX-99.2 · Exhibit EX-99.2
- Q3 2026 net product revenue $92.1M, up from $51.3M, with 73% generated in the U.S.
- IMCIVREE revenue increased 29% QoQ, supported by U.S. acquired hypothalamic obesity launch and 20% growth in reimbursed patients
- Bivamelagon advances to two global Phase 3 trials, targeting acquired hypothalamic obesity and Prader-Willi syndrome
- LG Chem royalty reduced to 1% from low-to-mid-single digits, but amended terms add $350M payments and a potential $200M commercial milestone
- $750M term loan facility secured at SOFR plus 4.60%, with $250M initially drawn and cash resources of $320.9M at September 30, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RHYTHM PHARMACEUTICALS, INC. 8-K filings
Get the next RYTM 8-K as it lands
Follow RYTM for push alerts, or ask the research agent what this filing means.